That is a good point that many don’t realize or consider. Whether they would be on leronlimab for a few years or the rest of their life isn’t clear to me at this point, but I would think for initial patient safety reasons, it would be until it was proven safe to be removed from treatment and no risk of increased CTCs or metastasis. I haven’t been calculating this (because even the annual numbers seem silly punching in the calculator), but is definitely a factor if cancer results are positive.
If I have time later today, I will try and put all these pieces together in a post for those here (RP stating either all cancers or a list of them that 50% over express CCR5 @ NC, US cancer stats, NP quote you reference, etc.). The market potential is enormous and if the cancer clinical results work, the “worldwide news” should definitely move the share price.
(0)
(0)
CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.